SG115193G - Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus - Google Patents

Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus

Info

Publication number
SG115193G
SG115193G SG115193A SG115193A SG115193G SG 115193 G SG115193 G SG 115193G SG 115193 A SG115193 A SG 115193A SG 115193 A SG115193 A SG 115193A SG 115193 G SG115193 G SG 115193G
Authority
SG
Singapore
Prior art keywords
complications
gamma
linolenic acid
treatment
diabetes mellitus
Prior art date
Application number
SG115193A
Other languages
English (en)
Inventor
David Frederick Horrobin
Charles Stewart
Hugh Carmichael
Goran A Jamal
Original Assignee
Efamol Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efamol Holdings filed Critical Efamol Holdings
Priority to SG115193A priority Critical patent/SG115193G/en
Publication of SG115193G publication Critical patent/SG115193G/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG115193A 1985-10-02 1993-10-18 Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus SG115193G (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG115193A SG115193G (en) 1985-10-02 1993-10-18 Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858524275A GB8524275D0 (en) 1985-10-02 1985-10-02 Pharmaceutical & dietary compositions
SG115193A SG115193G (en) 1985-10-02 1993-10-18 Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus

Publications (1)

Publication Number Publication Date
SG115193G true SG115193G (en) 1994-01-21

Family

ID=10586062

Family Applications (1)

Application Number Title Priority Date Filing Date
SG115193A SG115193G (en) 1985-10-02 1993-10-18 Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus

Country Status (14)

Country Link
US (1) US4826877A (fr)
EP (1) EP0218460B1 (fr)
JP (1) JPS6296421A (fr)
AT (1) ATE84414T1 (fr)
AU (1) AU586286B2 (fr)
CA (1) CA1279824C (fr)
DE (1) DE3687501T2 (fr)
ES (1) ES2043601T3 (fr)
GB (1) GB8524275D0 (fr)
GR (1) GR3007043T3 (fr)
HK (1) HK129393A (fr)
IE (1) IE59445B1 (fr)
SG (1) SG115193G (fr)
ZA (1) ZA867386B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU601238B2 (en) * 1986-11-13 1990-09-06 Efamol Holdings Plc A method of treatment of pregnancy induced hypertension
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
US5225441A (en) * 1987-06-18 1993-07-06 Block Drug Company, Inc. Treatment of periodontal disease
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US6140304A (en) * 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
AU620929B2 (en) * 1988-10-27 1992-02-27 Bar-Ilan University Method and compositions for treating alzheimer's disease, related dementias and epilepsy
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
ES2033193B1 (es) * 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
CA2101274C (fr) * 1991-01-24 1998-12-15 David J. Kyle Melanges d'huiles de microorganismes et leurs usages
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JPH0649479A (ja) * 1992-07-28 1994-02-22 Maruha Corp ω−３不飽和脂肪酸系化合物の安定化法
GB9300125D0 (en) * 1993-01-06 1993-03-03 Scotia Holdings Plc Compositions containing esters of unsaturated fatty acids
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
CA2164291C (fr) * 1993-06-09 2007-10-30 David John Kyle Methodes et compositions pharmaceutiques utiles pour le traitement de troubles neurologiques
IT1265340B1 (it) * 1993-07-14 1996-11-22 Istituto Biochimico Italiano Sostanze inibenti l'adp-ribosilazione proteica atte alla prevenzione delle complicanze del diabete mellito.
US5668174A (en) * 1993-12-29 1997-09-16 Kowa Tekuno Sachi Co., Ltd. Method of treating hyperparathyroidism
JPH07143862A (ja) * 1994-05-06 1995-06-06 Maruha Corp 脳機能改善効果を有する機能性食品。
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
GB9412925D0 (en) * 1994-06-28 1994-08-17 Scotia Holdings Plc Combination of aldose reductase inhibitors with gamma-linolenic (GLA) dihomogammalinolenic (DGLA) or arachidonic (AA) acids in the treatment of diabetic
US5968809A (en) * 1997-04-11 1999-10-19 Abbot Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
GB9715444D0 (en) * 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
IL125731A (en) 1998-08-11 2004-06-20 Zvi Yehuda Acylates which are products of neurotransmitters and essential fatty acids, pharmaceutical compositions containing them, use of such acylates in the manufacture of medicaments, and method for treating nervous diseases in non-human animals
US6677145B2 (en) 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
US20030163845A1 (en) * 1998-09-02 2003-08-28 Pradip Mukerji Elongase genes and uses thereof
DE19903095C2 (de) * 1999-01-27 2003-05-22 Nutrinova Gmbh Gewinnung von gamma-Linolensäure aus Protozoen der Gattung Colpidium
US6440931B1 (en) * 1999-02-23 2002-08-27 Natural Corporation Conjugated linoleic acid in treatment and prophylaxis of diabetes
US7070970B2 (en) 1999-08-23 2006-07-04 Abbott Laboratories Elongase genes and uses thereof
JP2003514855A (ja) * 1999-10-13 2003-04-22 チャコン，マルコ，エー． カロリー制限の効果を模倣した治療的介入
CA2301158A1 (fr) * 2000-03-24 2001-09-24 Stephen J. Allen Methodes de depistage de composes utilises pour moduler le metabolisme lipidique dans les maladies
EP1197550A3 (fr) * 2000-08-25 2002-11-20 Pfizer Products Inc. Méthodes et compositions pour diagnostiquer et traiter des troubles associés à l'angiogenèse
US6635451B2 (en) 2001-01-25 2003-10-21 Abbott Laboratories Desaturase genes and uses thereof
US7045683B2 (en) * 2001-05-04 2006-05-16 Abbott Laboratories Δ4-desaturase genes and uses thereof
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
ATE291910T1 (de) * 2001-05-30 2005-04-15 Laxdale Ltd Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
US7211656B2 (en) 2002-01-30 2007-05-01 Abbott Laboratories Desaturase genes, enzymes encoded thereby, and uses thereof
WO2003099216A2 (fr) 2002-05-22 2003-12-04 Monsanto Technology Llc Desaturases d'acides gras provenant des champignons
US7214491B2 (en) 2003-05-07 2007-05-08 E. I. Du Pont De Nemours And Company Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
US7238482B2 (en) * 2003-05-07 2007-07-03 E. I. Du Pont De Nemours And Company Production of polyunsaturated fatty acids in oleaginous yeasts
US7125672B2 (en) * 2003-05-07 2006-10-24 E. I. Du Pont De Nemours And Company Codon-optimized genes for the production of polyunsaturated fatty acids in oleaginous yeasts
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CA2436650A1 (fr) * 2003-08-06 2005-02-06 Naturia Inc. Compositions d'acides linoleniques conjugues : synthese, purification et utilisations
FI20060154A7 (fi) * 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
FR2860720A1 (fr) * 2003-10-09 2005-04-15 Jean Pascal Conduzorgues Nouvelles compositions pharmaceutiques pour traiter la xerostomie et maladies similaires
AU2004290051A1 (en) 2003-11-12 2005-05-26 E.I. Dupont De Nemours And Company Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oilseed plants and oleaginous yeast
BRPI0509944A (pt) 2004-04-16 2007-09-25 Monsanto Technology Llc expressão de dessaturases de ácido graxo em milho
AU2005262392A1 (en) * 2004-07-01 2006-01-19 Johnson & Johnson Vision Care, Inc. Compositions and methods for treating eye disorders and conditions
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
US7138391B2 (en) * 2004-08-09 2006-11-21 Silverbrook Research Pty Ltd Hydrophilizable and hydrophilic cyanine dyes
US7456270B2 (en) * 2004-09-01 2008-11-25 Abbott Laboratories Δ6-desaturase genes and uses thereof
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
ATE431155T1 (de) * 2007-03-07 2009-05-15 Indena Spa Formulierungen mit extrakten aus cynara scolymus und phaseolus vulgaris zur behandlung von adipositas
CA2739836A1 (fr) * 2008-10-06 2010-04-15 Tapas Das Genes de delta-8 desaturase, enzymes codees par ceux-ci et utilisations de ceux-ci
CA2743434C (fr) * 2008-11-14 2015-04-21 Bomi P. Framroze Procede pour diminuer le taux circulant du complexe lipoproteine de basse densite oxydee/beta-2-glycoproteine 1 pour le traitement de l'atherosclerose
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8188335B2 (en) 2009-07-17 2012-05-29 Abbott Laboratories Δ9-elongase for production of polyunsaturated fatty acid-enriched oils
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US9682055B2 (en) 2014-06-04 2017-06-20 Dignity Sciences Limted Pharmaceutical compositions comprising DGLA and use of same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4058594A (en) * 1974-04-25 1977-11-15 John Williams Immuno-suppressive agents
GB1580444A (en) * 1976-11-04 1980-12-03 Bio Oil Res Pharmaceutical compositions
IE47777B1 (en) * 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
IE49783B1 (en) * 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
EP0071357B1 (fr) * 1981-07-14 1985-01-02 Efamol Limited Composition pharmaceutique et diététique pour augmenter la production de la pg de la série l
EP0087865B1 (fr) * 1982-03-01 1986-10-01 Efamol Limited Composition pharmaceutique
EP0092076B1 (fr) * 1982-04-16 1986-12-17 Societe Des Produits Nestle S.A. Composition lipidique destinée à l'alimentation orale, entérale ou parentérale
US4472432A (en) * 1982-05-12 1984-09-18 Inabata & Co., Ltd. Medicinal use of α,β-unsaturated fatty acids
GB2134782B (en) * 1982-09-22 1987-03-04 Sentrachem Ltd Anti-cancer compositions containing higher fatty acids
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8326130D0 (en) * 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids
FR2558154B1 (fr) * 1984-01-16 1986-08-29 Pf Medicament Acides gras ramifies en c10 a c20 utiles en tant que medicaments, et leur procede de preparation

Also Published As

Publication number Publication date
EP0218460A3 (en) 1989-08-09
ES2043601T3 (es) 1994-01-01
IE862543L (en) 1987-04-02
GB8524275D0 (en) 1985-11-06
GR3007043T3 (fr) 1993-07-30
US4826877A (en) 1989-05-02
EP0218460A2 (fr) 1987-04-15
HK129393A (en) 1993-12-03
AU586286B2 (en) 1989-07-06
JPS6296421A (ja) 1987-05-02
AU6340786A (en) 1987-04-09
DE3687501D1 (de) 1993-02-25
DE3687501T2 (de) 1993-05-19
ATE84414T1 (de) 1993-01-15
EP0218460B1 (fr) 1993-01-13
ZA867386B (en) 1987-10-28
IE59445B1 (en) 1994-02-23
CA1279824C (fr) 1991-02-05

Similar Documents

Publication Publication Date Title
SG115193G (en) Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
EP0440307A3 (fr) Composition pharmaceutique et diététique
BG60261B2 (en) Lon-acting formulation of cefaclor
IE882583L (en) Treatment of wounds
ZA885192B (en) Pharmaceutical preparations
WO1996015784A3 (fr) Acides 2,2-dichloroalcanecarboxyliques, leur procede de preparation, medicaments les contenant, et leur utilisation dans le traitement de la resistance insulinique
IL90056A0 (en) Topical pharmaceutical compositions containing 4-quinoline carboxylic acid derivatives
AU1176688A (en) Method of treatment comprising transcutaneous administration of prostaglandin E1 derivatives
AU5911590A (en) Pharmaceutical and dietary uses of fatty acids
HUT57204A (en) Process for producing 4-fluoro-2-///4-methoxy-2-pyridinyl/-methyl/-sulfinyl/-1h-benzimidazol with gastric acid secration-diminishing activity and pharmaceutical compositions containing them
CA2067374A1 (fr) Promoteur de l'osteogenese
GB1474424A (en) Pharmaceutical composition for treating diabetic ketoacidosis
IE861744L (en) Composition for treatment of premenstrual syndrome
CA2038025A1 (fr) Derives de l'alkylenedioxybenzene optiquement actifs et leur utilisation a des fins therapeutiques
IE46171L (en) N-pyrrolidinylmethylbenzamide derivative.
EP0193164A3 (fr) Préparations pharmaceutiques à libération prolongée contenant de la 2-nitroxyméthyl-6-chloropyridine, leur procédé de préparation et leur utilisation
HK8994A (en) Medicament for treatment of pregnancy-induced hypertension
MX9703359A (es) Acidos 2,2-dicloroalcancarboxilicos, proceso para su preparacion, medicamentos que los contienen y su uso para tratar resistencia a la insulina.